Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MGX Stock Forecast 2025-2026
$1.56
Current Price
$58.32M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MGX Price Targets
+1,246.2%
To High Target of $21.00
+669.2%
To Median Target of $12.00
+348.7%
To Low Target of $7.00
MGX Price Momentum
+3.3%
1 Week Change
+5.4%
1 Month Change
-77.7%
1 Year Change
-56.8%
Year-to-Date Change
-80.9%
From 52W High of $8.18
+26.8%
From 52W Low of $1.23
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Metagenomi (MGX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MGX and similar high-potential opportunities.
Latest MGX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, MGX has a bullish consensus with a median price target of $12.00 (ranging from $7.00 to $21.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $1.56, the median forecast implies a 669.2% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Geulah Livshits at Chardan Capital, projecting a 1,246.2% upside. Conversely, the most conservative target is provided by Mitchell Kapoor at HC Wainwright & Co., suggesting a 348.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGX Analyst Ratings
6
Buy
1
Hold
0
Sell
MGX Price Target Range
Low
$7.00
Average
$12.00
High
$21.00
Current: $1.56
Latest MGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $12.00 |
| May 14, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $16.00 |
| Apr 3, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $7.00 |
| Mar 18, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $20.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $14.00 |
| Nov 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $7.00 |
| Nov 20, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $7.00 |
| Sep 6, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $7.00 |
| Sep 5, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Aug 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $7.00 |
| Aug 19, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Aug 15, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $17.00 |
| Jul 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $10.00 |
| May 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $10.00 |
| May 7, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Initiates | $10.00 |
| May 2, 2024 | JP Morgan | Brian Cheng | Neutral | Downgrade | $6.00 |
| Mar 28, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $21.00 |
| Mar 5, 2024 | JP Morgan | Brian Cheng | Overweight | Initiates | $16.00 |
| Mar 5, 2024 | Jefferies | Maury Raycroft | Buy | Initiates | $23.00 |
Metagenomi Inc. (MGX) Competitors
The following stocks are similar to Metagenomi based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Metagenomi Inc. (MGX) Financial Data
Metagenomi Inc. has a market capitalization of $58.32M with a P/E ratio of 0.0x. The company generates $45.26M in trailing twelve-month revenue with a -172.2% profit margin.
Revenue growth is -63.0% quarter-over-quarter, while maintaining an operating margin of -674.1% and return on equity of -33.2%.
Valuation Metrics
Market Cap
$58.32M
Enterprise Value
$-146,453,792
P/E Ratio
0.0x
PEG Ratio
-0.5x
Price/Sales
1.3x
Growth & Margins
Revenue Growth (YoY)
-63.0%
Gross Margin
N/A
Operating Margin
-674.1%
Net Margin
-172.2%
EPS Growth
-22.5%
Financial Health
Cash/Price Ratio
+425.8%
Current Ratio
6.9x
Debt/Equity
19.5x
ROE
-33.2%
ROA
-24.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Metagenomi Inc. (MGX) Business Model
About Metagenomi Inc.
What They Do
Develops advanced gene editing technologies.
Business Model
Metagenomi Inc. generates revenue by offering its proprietary gene editing platform to various sectors, including healthcare, agriculture, and industrial biotechnology. The company focuses on creating precise genetic modifications that can address genetic disorders, enhance crop resilience, and improve bio-based manufacturing processes, thereby tapping into the growing demand for innovative biotech solutions.
Additional Information
As a key player in the biotechnology industry, Metagenomi is well-positioned to capitalize on the increasing interest in gene editing technologies. Its innovative approach not only aims to provide therapeutic solutions but also enhances sustainability in agriculture and manufacturing, making it an attractive investment opportunity.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
202
CEO
Dr. Brian Charles Thomas Ph.D.
Country
United States
IPO Year
2024
Website
metagenomi.coMetagenomi Inc. (MGX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates
Metagenomi (MGX) delivered earnings and revenue surprises of -9.68% and 52.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 13, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
A significant advancement in extrahepatic in vivo gene editing has been achieved, focusing on all-in-one delivery to the central nervous system, which may enhance treatment options for neurological disorders.
Why It Matters
Advancements in gene editing for CNS disorders could lead to breakthrough therapies, enhancing market potential for biotech firms and driving stock prices in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A nonhuman primate study in hemophilia A showed promising factor VIII activity and a durable response lasting about 19 months, along with a positive safety profile.
Why It Matters
Positive results from the NHP study on hemophilia A suggest potential for a successful treatment, which could lead to increased market interest and investment in related biotech firms.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Metagenomi reported a quarterly loss of $0.68 per share, worse than the expected loss of $0.62, but improved from a loss of $1.19 per share a year earlier.
Why It Matters
Metagenomi's larger-than-expected quarterly loss may signal ongoing challenges, impacting investor confidence and stock performance, despite improvement from last year’s loss.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Metagenomi, Inc. (Nasdaq: MGX) will present at TIDES USA 2025 and ASGCT 2025 Annual Meeting, showcasing its gene editing advancements. Events are scheduled for May 13-22, 2025.
Why It Matters
Metagenomi's presentations at major scientific meetings could enhance its visibility and credibility, potentially attracting investors and impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A presentation at the ASH 66th Annual Meeting showed sustained Factor VIII activity for over 16 months in a nonhuman primate study related to Hemophilia A.
Why It Matters
Sustained FVIII activity in nonhuman primates suggests potential for long-lasting hemophilia A treatments, which could boost market confidence and drive stock prices for biotech firms in this sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Metagenomi, Inc. (Nasdaq: MGX) announced the successful integration of a large gene into human cells using its compact CAST system, with further advancements expected in 2025.
Why It Matters
Metagenomi's breakthrough in gene editing can enhance therapeutic delivery, potentially leading to groundbreaking treatments and driving investor interest in its stock performance and future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MGX Stock
What is Metagenomi Inc.'s (MGX) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Metagenomi Inc. (MGX) has a median price target of $12.00. The highest price target is $21.00 and the lowest is $7.00.
Is MGX stock a good investment in 2025?
According to current analyst ratings, MGX has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.56. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MGX stock?
Wall Street analysts predict MGX stock could reach $12.00 in the next 12 months. This represents a 669.2% increase from the current price of $1.56. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Metagenomi Inc.'s business model?
Metagenomi Inc. generates revenue by offering its proprietary gene editing platform to various sectors, including healthcare, agriculture, and industrial biotechnology. The company focuses on creating precise genetic modifications that can address genetic disorders, enhance crop resilience, and improve bio-based manufacturing processes, thereby tapping into the growing demand for innovative biotech solutions.
What is the highest forecasted price for MGX Metagenomi Inc.?
The highest price target for MGX is $21.00 from Geulah Livshits at Chardan Capital, which represents a 1,246.2% increase from the current price of $1.56.
What is the lowest forecasted price for MGX Metagenomi Inc.?
The lowest price target for MGX is $7.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a 348.7% increase from the current price of $1.56.
What is the overall MGX consensus from analysts for Metagenomi Inc.?
The overall analyst consensus for MGX is bullish. Out of 7 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are MGX stock price projections?
Stock price projections, including those for Metagenomi Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 9:08 AM UTC